Staging for prostate cancer
Open Access
- 8 January 2007
- Vol. 109 (2) , 213-220
- https://doi.org/10.1002/cncr.22403
Abstract
BACKGROUND.: The American Joint Committee on Cancer (AJCC) staging system for prostate cancer is based primarily based on clinical tumor (T) classification. In this article, the authors summarize arguments for incorporating additional pretreatment parameters and creating a new staging system for prostate cancer.METHODS.: Men with localized prostate cancer who received treatment with external beam radiation alone were analyzed using the 1997 AJCC staging system compared with a system that included pretreatment prostate‐specific antigen (pPSA) level and Gleason score (GS). Multivariate analyses using a Cox proportional‐hazards model were carried out to evaluate T classification, GS, and pPSA as predictors of overall survival (OS), disease‐specific survival (DSS), and freedom from PSA failure (FFPF).RESULTS.: Based on pretreatment characteristics in a series of contemporary patients, only 0.6% of patients were classified with AJCC stage I disease, 16.0% were classified with AJCC stage III disease, and 83.4% were classified with AJCC stage II disease. Multivariate analyses indicated the independent statistical significance of T classification, GS, and pPSA in predicting OS, DSS, and FFPF (model chi‐square value,P< .0001 for each). Using these 3 predictors, subsets of patients who had similar outcomes were combined to provide examples of the insensitivity of the AJCC system for predicting outcomes. Incorporating pPSA and GS allowed the identification of differences in OS, DSS, and FFPF for subsets of patients with AJCC stage II disease (P< .0001,P= .005, andP< .0001, respectively).CONCLUSIONS.: The current AJCC staging system does not divide contemporary patients with prostate cancer into prognostic subgroups and does not identify patients who have comparable biochemical control and survival. The AJCC staging system for prostate cancer should be changed to incorporate pPSA, GS, and risk stratification. Cancer 2007. © 2006 American Cancer Society.Keywords
This publication has 34 references indexed in Scilit:
- Impact of the Percentage of Positive Prostate Cores on Prostate Cancer–Specific Mortality for Patients With Low or Favorable Intermediate-Risk DiseaseJournal of Clinical Oncology, 2004
- Preoperative PSA Velocity and the Risk of Death from Prostate Cancer after Radical ProstatectomyNew England Journal of Medicine, 2004
- Prevalence of Prostate Cancer among Men with a Prostate-Specific Antigen Level ≤4.0 ng per MilliliterNew England Journal of Medicine, 2004
- 10-Year Outcome for Men With Localized Prostate Cancer Treated With External Radiation Therapy:: Results of a Cohort StudyJournal of Urology, 2004
- Time Trends in Clinical Risk Stratification for Prostate Cancer: Implications for Outcomes (Data From CaPSURE)Journal of Urology, 2003
- A Preoperative Nomogram Identifying Decreased Risk of Positive Pelvic Lymph Nodes in Patients With Prostate CancerJournal of Urology, 2003
- Pretreatment Predictors of Time to Cancer Specific Death After Prostate Specific Antigen FailureJournal of Urology, 2003
- 2135 3D conformal radiotherapy improves PSA failure rates for intermediate risk patients at conventional dosesInternational Journal of Radiation Oncology*Biology*Physics, 1999
- Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancerInternational Journal of Radiation Oncology*Biology*Physics, 1998
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958